2026-05-09 Scientific Evidence Assessment of NMNH in the U.S. Market: A 2026 Review of FDA NDI Status and NAD+ Precursor ComplianceThis article reviews the NMNH FDA NDI Status discussion in the 2026 U.S. market and explains why FDA NDI, GRAS, and FDA approval should not be confused. Following the NMN FDA Reversal 2025, NMNH should still be evaluated independently through ingredient-specific safety data, scientific evidence, intended use, and regulatory documentation. UthPeak® NMNH’s self-affirmed GRAS status provides a safety-oriented foundation for brands seeking responsible NAD+ precursor innovation in the U.S. market.